journal article·2021-03-24Open access

Critical Parameters to Improve Pancreatic Cancer Treatment Using Magnetic Hyperthermia: Field Conditions, Immune Response, and Particle Biodistribution

Lilianne Beola, Valeria Grazú, Yilian Fernández-Afonso, Raluca M. Fratila, Marcelo de las Heras, Jesús M. de la Fuente, Lucía Gutiérrez, Laura Asín

ACS Applied Materials & Interfaces· Volume 13· Issue 11

Abstract

Magnetic hyperthermia (MH) was used to treat a murine model of pancreatic cancer. This type of cancer is generally characterized by the presence of dense stroma that acts as a barrier for chemotherapeutic treatments. Several alternating magnetic field (AMF) conditions were evaluated using three-dimensional (3D) cell culture models loaded with magnetic nanoparticles (MNPs) to determine which conditions were producing a strong effect on the cell viability. Once the optimal AMF conditions were selected, in vivo experiments were carried out using similar frequency and field amplitude parameters. A marker of the immune response activation, calreticulin (CALR), was evaluated in cells from a xenograft tumor model after the MH treatment. Moreover, the distribution of nanoparticles within the tumor tissue was assessed by histological analysis of tumor sections, observing that the exposure to the alternating magnetic field resulted in the migration of particles toward the inner parts of the tumor. Finally, a relationship between an inadequate body biodistribution of the particles after their intratumoral injection and a significant decrease in the effectiveness of the MH treatment was found. Animals in which most of the particles remained in the tumor area after injection showed higher reductions in the tumor volume growth in comparison with those animals in which part of the particles were found also in the liver and spleen. Therefore, our results point out several factors that should be considered to improve the treatment effectiveness of pancreatic cancer by magnetic hyperthermia.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Microfluidic and Bio-sensing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC─Universidad de Zaragoza, 50018 Zaragoza, Spain

Department of Analytical Chemistry, Universidad de Zaragoza, 50018 Zaragoza, Spain

Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 50018 Zaragoza, Spain

Department of Animal Pathology, Universidad de Zaragoza, 50009 Zaragoza, Spain

Funding

Universidad de Zaragoza · Ministerio de Ciencia, Innovaci?n y Universidades · European Commission · Ministerio de Econom?a y Competitividad

References (70)

Show source-provided references
1. 10.4251/wjgo.v10.i8.20210.4251/wjgo.v10.i8.202 ↗
2. 10.1158/0008-5472.CAN-18-133410.1158/0008-5472.CAN-18-1334 ↗
3. 10.3390/cancers1105058810.3390/cancers11050588 ↗
4. 10.1021/nn500962q10.1021/nn500962q ↗
5. 10.3389/fbioe.2019.0030710.3389/fbioe.2019.00307 ↗
6. 10.1021/acsami.8b1827010.1021/acsami.8b18270 ↗
7. 10.1039/C4NR03482A10.1039/C4NR03482A ↗
8. 10.1007/s11060-010-0389-010.1007/s11060-010-0389-0 ↗
9. 10.3109/0265673100374574010.3109/02656731003745740 ↗
10. 10.1515/bmt-2015-005210.1515/bmt-2015-0052 ↗
11. 10.1007/s11095-014-1417-010.1007/s11095-014-1417-0 ↗
12. 10.1016/j.nano.2020.10218310.1016/j.nano.2020.102183 ↗
13. 10.3892/or.2011.156710.3892/or.2011.1567 ↗
14. 10.2147/IJN.S10857710.2147/IJN.S108577 ↗
15. 10.1080/02656736.2020.179851410.1080/02656736.2020.1798514 ↗
16. 10.1021/acsami.8b1845110.1021/acsami.8b18451 ↗
17. 10.1002/adma.20200371210.1002/adma.202003712 ↗
18. 10.1021/acs.jpcc.5b0255510.1021/acs.jpcc.5b02555 ↗
19. 10.1038/nrc338010.1038/nrc3380 ↗
20. 10.1038/nm152310.1038/nm1523 ↗
21. 10.1021/acsnano.9b0197910.1021/acsnano.9b01979 ↗
22. 10.1186/s12943-018-0842-910.1186/s12943-018-0842-9 ↗
23. 10.1021/acs.nanolett.9b0057910.1021/acs.nanolett.9b00579 ↗
24. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
25. Beola L. · 2019 · 31710.1016/B978-0-12-813928-8.00012-0 ↗
26. 10.1021/acsami.0c1290010.1021/acsami.0c12900 ↗
27. 10.1021/nn204543c10.1021/nn204543c ↗
28. 10.1016/j.jmmm.2006.10.115610.1016/j.jmmm.2006.10.1156 ↗
29. 10.3109/02656736.2013.82299310.3109/02656736.2013.822993 ↗
30. 10.1002/anie.20130583510.1002/anie.201305835 ↗
31. 10.1002/adfm.20167001510.1002/adfm.201670015 ↗
32. 10.1063/1.348888110.1063/1.3488881 ↗
33. 10.7150/thno.919910.7150/thno.9199 ↗
34. Hoopes, P. J.; Mazur, C. M.; Osterberg, B.; Song, A.; Gladstone, D. J.; Steinmetz, N. F.; Veliz, F. A.; Bursey, A. A.; Wagner, R. J.; Fiering, S. N. In Effect of Intra-Tumoral Magnetic NanoparticleHyperthermia and Viral Nanoparticle Immunogenicity on Primary and Metastatic Cancer, Energy-based Treatment of Tissue and Assessment IX. International Society for Optics and Photonics, 2017; pp 100660G-1–100660G-8.10.1117/12.2256062 ↗
35. 10.1016/j.biomaterials.2016.08.01510.1016/j.biomaterials.2016.08.015 ↗
36. 10.1021/acsami.8b0239810.1021/acsami.8b02398 ↗
37. 10.1016/j.phrs.2017.07.01010.1016/j.phrs.2017.07.010 ↗
38. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
39. 10.1387/ijdb.150061pa10.1387/ijdb.150061pa ↗
40. 10.1038/srep2164810.1038/srep21648 ↗
41. 10.1371/journal.pone.020675910.1371/journal.pone.0206759 ↗
42. 10.2147/CMAR.S24787610.2147/CMAR.S247876 ↗
43. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
44. 10.1021/acsnano.8b0620110.1021/acsnano.8b06201 ↗
45. Wang S. · Am. J. Cancer Res. · 2018 · 8 · 1933
46. 10.1038/s41467-020-17380-510.1038/s41467-020-17380-5 ↗
47. 10.1016/j.biomaterials.2019.11937010.1016/j.biomaterials.2019.119370 ↗
48. 10.1021/acsnano.9b0832010.1021/acsnano.9b08320 ↗
49. 10.1016/j.jconrel.2019.05.03610.1016/j.jconrel.2019.05.036 ↗
50. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
51. 10.1126/science.aaf109810.1126/science.aaf1098 ↗
52. 10.1186/s13058-015-0576-110.1186/s13058-015-0576-1 ↗
53. 10.1016/S0304-8853(02)00634-010.1016/S0304-8853(02)00634-0 ↗
54. 10.1021/acsnano.5b0724910.1021/acsnano.5b07249 ↗
55. 10.1002/adma.20140250910.1002/adma.201402509 ↗
56. 10.1088/0957-4484/22/50/50510210.1088/0957-4484/22/50/505102 ↗
57. 10.1088/0957-4484/22/34/34510110.1088/0957-4484/22/34/345101 ↗
58. Javidi M. · J. Biomed. Phys. Eng. · 2014 · 4 · 151
59. 10.4236/ojmi.2016.6100110.4236/ojmi.2016.61001 ↗
60. 10.3109/02656736.2011.58485610.3109/02656736.2011.584856 ↗
61. 10.1073/pnas.121335310910.1073/pnas.1213353109 ↗
62. 10.1088/0031-9155/52/16/02210.1088/0031-9155/52/16/022 ↗
63. 10.1021/acsami.7b1864810.1021/acsami.7b18648 ↗
64. 10.1016/j.actbio.2017.05.04710.1016/j.actbio.2017.05.047 ↗
65. 10.1039/C5NR03780H10.1039/C5NR03780H ↗
66. 10.1016/j.jconrel.2013.07.01910.1016/j.jconrel.2013.07.019 ↗
67. 10.1088/0022-3727/44/25/25500210.1088/0022-3727/44/25/255002 ↗
68. 10.1039/C3CP54763A10.1039/C3CP54763A ↗
69. 10.1021/ja038085210.1021/ja0380852 ↗
70. 10.1039/c0nr00104j10.1039/c0nr00104j ↗